Skip to main content

Genitourinary

Protocols

Bladder

UGUAJNIV

Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab

UGUAJNIV4

Adjuvant Treatment of Resected Urothelial Carcinoma using 4-Weekly Nivolumab

GUAJPG

Adjuvant therapy for urothelial carcinoma using CISplatin and gemcitabine

GUAVEV

Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin

GUAVPEM

Treatment of Locally Advanced or Metastatic Urothelial Carcinoma Using Pembrolizumab

GUAVPEM6

Treatment of Locally Advanced or Metastatic Urothelial Carcinoma Using 6-Weekly Pembrolizumab

GUAVPG

Palliative therapy for urothelial carcinoma using CISplatin and gemcitabine

GUBAVE

Maintenance Therapy of Locally Advanced or Metastatic Urothelial Carcinoma using Avelumab

GUBCG

Therapy for High or Intermediate Risk Non-Muscle Invasive Bladder Cancer using BCG

GUBCGIFN (deleted 01 Jan 2022)

GUBDDMVAC

Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, vinBLAStine, DOXOrubicin and CISplatin

GUBGEM

Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine

GUBGEMDOC

Intravesical Therapy for Non-Muscle Invasive Bladder Cancer Using Gemcitabine and Docetaxel

GUBMITO

Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Mitomycin

GUBPWRT

Treatment of Locally Advanced Bladder Cancer with Weekly CISplatin and Concurrent Radiation

GUMVAC

Therapy for transitional cell cancers of the urothelium using Methotrexate, vinBLAstine, DOXOrubicin and CISplatin

GUNAJPG

Neo-Adjuvant Therapy for Urothelial Carcinoma Using CISplatin and Gemcitabine

Top

Prostate

GUMCSPABI

Therapy for Metastatic Castration Sensitive Prostate Cancer using Abiraterone and predniSONE

GUMCSPAPA

Treatment of Metastatic Castration Sensitive Prostate Cancer using Apalutamide

GUMCSPENZ

Treatment for Metastatic Castration Sensitive Prostate Cancer using Enzalutamide

UGUNMPDAR

Non- Metastatic Castration Resistant Prostate Cancer Using Darolutamide

UGUNMPENZ

Therapy for Non-Metastatic Castration Resistant Prostate Cancer Using Enzalutamide

UGUPABI

Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and predniSONE

UGUPAPA

Treatment of Non- Metastatic Castration Resistant Prostate Cancer Using Apalutamide

GUPCABA

Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Cabazitaxel and predniSONE

GUPDOC

Palliative Therapy for Metastatic Hormone Refractory Prostate Cancer Using DOCEtaxel and predniSONE

GUPDOCADT

First-Line Treatment of Castration Sensitive, Metastatic Prostate Cancer Using DOCEtaxel and Androgen Deprivation Therapy

UGUPENZ

Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Enzalutamide

GUPHDBIC

Treatment of Prostate Cancer with High Dose Bicalutamide

GUPLHRH

Therapy for Prostate Cancer Using LHRH agonist (Goserelin, Leuprolide or Buserelin)

GUPLHRHA

Therapy for Advanced Prostate Cancer Using LHRH antagonist Degarelix

GUPMX

Palliative therapy for hormone-refractory prostate cancer using mitoXANTRONE and predniSONE

GUPNSAA

Non-Steroidal Treatment of Prostate Cancer

UGUPOLAP

Treatment of Metastatic Castration-Resistant Prostate Cancer using Olaparib

GUPRAD

Therapy for Metastatic Castration Resistant Prostate Cancer Using Radium-223

Top

Testicular

GUBEP

Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and CISplatin

GUEP

Therapy for nonseminoma germ cell cancer using Etoposide-CISplatin

GUSCARB

Adjuvant therapy for stage I high risk seminoma using CARBOplatin

GUTAXGEM

Palliative therapy for germ cell cancers using PACLitaxel and gemcitabine

GUTIP

Therapy for Relapsed Testicular Germ Cell cancer using PACLitaxel, lfosfamide and CISplatin (TIP)

GUVEIP

Consolidation/ Salvage Treatment for Germ Cell Cancer Using VinBLAstine, CISplatin, Ifosfamide and Mesna

GUVIP2

Consolidation and Salvage Therapy for Nonseminoma Using Etoposide, CISplatin, Ifosfamide, Mesna

Top

Renal/Kidney

GUAJPEM

Adjuvant Treatment of Resected Renal Cell Carcinoma using Pembrolizumab

GUAJPEM6

Adjuvant Treatment of Resected Renal Cell Carcinoma using 6-Weekly Pembrolizumab

GUAVIPNI

Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Ipilimumab and Nivolumab

GUAVNIV

Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab

GUAVNIV4

Treatment of Metastatic or Advanced Renal Cell Carcinoma Using 4-Weekly Nivolumab

GUAVPEMAX

Treatment of Metastatic Renal Cell Carcinoma Using Pembrolizumab and aXitinib

GUAVPEML

Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Lenvatinib

GUAVPEML6

Treatment of Metastatic Renal Cell Carcinoma using 6-weekly Pembrolizumab and Lenvatinib

GUAXIT

Therapy for Metastatic Renal Cell Carcinoma Using Axitinib

GUCABO

>Therapy for Metastatic Renal Cell Carcinoma Using Cabozantinib

GUEVER

Therapy for Advanced Renal Cancer Using Everolimus

GUPAZO

Palliative Therapy for Renal Cell Carcinoma Using Pazopanib

GUSORAF

Palliative Therapy for Renal Cell Carcinoma Using SORAfenib

GUSUNI

Palliative Therapy for Renal Cell Carcinoma Using SUNItinib

GUTEM

Therapy for Advanced Renal Cancer Using Temsirolimus

Top

Miscellaneous

GUAVD

Palliative Therapy for Advanced Adrenal Cortical Cancer Using DOXOrubicin

GUEDPM

Treatment of Metastatic Adrenocortical Cancer with Etoposide, DOXOrubicin, CISplatin and Mitotane

GUFUPRT

Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System Using Fluorouracil and CISplatin with Radiation

GUMITO

Treatment of Adrenal Cortical Cancer with Mitotane

GUSCPE

Palliative Therapy of Extensive Stage Genitourinary Small Cell Tumours with a Platinum and Etoposide

GUSCPERT

Therapy of Genitourinary Small Cell Tumours with a Platin and Etoposide with Radiation


Funding Algorithm

The funding algorithm provides information on what anti-cancer systemic therapy treatments are covered on the BC Cancer Benefit Drug List (formulary). It may not be a complete list of all treatment options that may be available and recommended by the treating physician.
Terms of use
The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. 

Use of these documents is at your own risk and is subject to BC Cancer's Terms of Use.


Tab Heading
SOURCE: Genitourinary ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2023 Provincial Health Services Authority